A Study of Qishenyiqi Dripping Pills in Healthy Participants

A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase 1 Study to Evaluate the Safety and Tolerability of Continuous Oral Treatment With Qishenyiqi Dripping Pills in Healthy Participants

This study will evaluate the safety and tolerability of Qishenyiqi Dripping Pills in healthy participants, following oral administration with multiple escalating dose of it.

Study Overview

• Status: Completed
• Conditions: Healthy Participants
• Intervention / Treatment: Drug: Qishenyiqi dripping pills, 6 bags; Drug: Qishenyiqi dripping pills, 9 bags; Drug: Qishenyiqi dripping pills, 12 bags; Drug: Qishenyiqi dripping pills placebo, 6 bags; Drug: Qishenyiqi dripping pills placebo, 9 bags; Drug: Qishenyiqi dripping pills placebo, 12 bags

Detailed Description

Qishenyiqi dripping pills, which are made of Huangqi, Danshen, Sanqi, active ingredients of Jiangxiang, have the efficacy of beneficial effects of qi and pulse, blood circulation and pain relief.

This study is a randomized, double-blind, placebo-controlled, dose-escalation design study, including three cohorts and 36 healthy participants. Within each cohort, participant will receive Qishenyiqi dripping pills at the selected dose level by oral administration three times a day for 28 consecutive days.

• Study Type: Interventional
• Enrollment (Actual): 36
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Tianjin
    • Tianjin, Tianjin, China
      • The First Teaching Hospital of Tianjin University of TCM

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 50 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Healthy volunteers, male or female, aged 18-50 years (including the boundary value);
• Participants weigh at least 50.0 kg in male and 45.0 kg in female with a body mass index of all subjects between 19 and 26kg/m2 (including the boundary value);
• Participants are willing to have no pregnancy program and take effective contraceptive measures voluntarily since signing informed consent form to 3 months after the last administration;
• Participants are willing to sign Independent Ethics Committee (IEC)-approved informed consent form and able to understand and comply with study procedures.

Exclusion Criteria:

• Participants with allergic constitution or have a history of allergy to drug or food;
• Participants with diseases or physiological conditions that may affect the study, including but not limited to diseases of the nervous, mental, respiratory, cardiovascular, digestive, blood and lymphatic, endocrine, musculoskeletal systems, liver and kidney dysfunction;
• Participants who have any clinically significant abnormalities in vital signs, physical examination, electrocardiogram, chest radiograph, abdominal ultrasound and laboratory examination;
• Participants who have positive test for hepatitis B virus surface antigen (except surface antibodies), hepatitis C virus antibody, human immunodeficiency virus antibody and treponema pallidum antibody;
• Women who are in the state of pregnancy or lactation;
• Participants who have a history of drug abuse or a positive test result for drug abuse at screening;
• Participants who have smoked more than 5 cigarette per day or used a considerable amount of nicotine-containing products within the previous 3 months, and could not quit smoking during the experiment;
• Participants who have been drinking more than 14 units of alcohol per week within the previous 3 months (1 unit ≈285 mL beer with 3.5% alcohol or 25 mL spirits with 40% alcohol or 85 mL wines with 12% alcohol), or positive test for alcohol, or could not abstain from drinking during the trial;
• Participants who have taken any prescription drugs (including prescription, nonprescription, herbal medicine, dietary supplement such as vitamin product and calcium tablet) within 4 weeks before administration of investigational drugs;
• Participants who have difficulty in venous blood collection or history of fainting blood or needles;
• Participants who have participated in any drug clinical trial within 3 months and have taken the experimental drug or plan to participate in other clinical trials during the trial period;
• Participants who have donated or lost blood ≥200 mL within 3 months or received blood transfusion or used blood products, or have blood donation plan during the trial period;
• Judged by the investigator, participants have poor compliance or have other factors such as clinical, social or family that should not be included in the trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Active dosage group 1; Qishenyiqi dripping pills, 3.12g, oral, three times a day	Drug: Qishenyiqi dripping pills, 6 bags; 28 consecutive days
Active Comparator: Active dosage group 2; Qishenyiqi dripping pills, 4.68g, oral, three times a day	Drug: Qishenyiqi dripping pills, 9 bags; 28 consecutive days
Active Comparator: Active dosage group 3; Qishenyiqi dripping pills, 6.24g, oral, three times a day	Drug: Qishenyiqi dripping pills, 12 bags; 28 consecutive days
Placebo Comparator: Control dosage group 1; Qishenyiqi dripping pills placebo, 3.12g, oral, three times a day	Drug: Qishenyiqi dripping pills placebo, 6 bags; 28 consecutive days
Placebo Comparator: Control dosage group 2; Qishenyiqi dripping pills placebo, 4.68g, oral, three times a day	Drug: Qishenyiqi dripping pills placebo, 9 bags; 28 consecutive days
Placebo Comparator: Control dosage group 3; Qishenyiqi dripping pills placebo, 6.24g, oral, three times a day	Drug: Qishenyiqi dripping pills placebo, 12 bags; 28 consecutive days

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse events	Observe all the adverse events of all participants administrated orally with Qishenyiqi dripping pills.	From screening (2 weeks in advance) till follow-up visit (up to 1week)
Number of participants with abnormal vital signs index (body temperature)	To investigate the safety and tolerability of Qishenyiqi dripping pills following oral administration in healthy participants.	From screening (2 weeks in advance) till the end of trial period (Day 29)
Number of participants with abnormal vital signs index (pulse rate)	To investigate the safety and tolerability of Qishenyiqi dripping pills following oral administration in healthy participants.	From screening (2 weeks in advance) till the end of trial period (Day 29)
Number of participants with abnormal vital signs index (respiratory rate)	To investigate the safety and tolerability of Qishenyiqi dripping pills following oral administration in healthy participants.	From screening (2 weeks in advance) till the end of trial period (Day 29)
Number of participants with abnormal vital signs index (blood pressure)	To investigate the safety and tolerability of Qishenyiqi dripping pills following oral administration in healthy participants.	From screening (2 weeks in advance) till the end of trial period (Day 29)
Physical examination	The complete physical examinations will include an assessment of the general appearance, skin, cardiovascular, abdomen, head, and neck, lymph nodes, musculoskeletal and neurological systems.	screening (2 weeks in advance), Day 8, Day 15, Day 22, Day 29
Number of participants with abnormal laboratory assessments (blood routine test)	To investigate the safety and tolerability of Qishenyiqi dripping pills following oral administration in healthy participants.	screening (2 weeks in advance), Day 8, Day 15, Day 22, Day 29
Number of participants with abnormal laboratory assessments (blood biochemical test)	To investigate the safety and tolerability of Qishenyiqi dripping pills following oral administration in healthy participants.	screening (2 weeks in advance), Day 8, Day 15, Day 22, Day 29
Number of participants with abnormal laboratory assessments (coagulation function test)	To investigate the safety and tolerability of Qishenyiqi dripping pills following oral administration in healthy participants.	screening (2 weeks in advance), Day 8, Day 15, Day 22, Day 29
Number of participants with abnormal laboratory assessments (urinalysis routine test)	To investigate the safety and tolerability of Qishenyiqi dripping pills following oral administration in healthy participants.	screening (2 weeks in advance), Day 8, Day 15, Day 22, Day 29
Number of participants with abnormal laboratory assessments (fecal routine test)	To investigate the safety and tolerability of Qishenyiqi dripping pills following oral administration in healthy participants.	screening (2 weeks in advance), Day 8, Day 15, Day 22, Day 29
Number of participants with abnormal findings in 12-lead safety Electrocardiogram (ECG)	To investigate the safety and tolerability of Qishenyiqi dripping pills following oral administration in healthy participants.	screening (2 weeks in advance), Day 8, Day 15, Day 22, Day 29

Collaborators and Investigators

• Sponsor: Tasly Pharmaceutical Group Co., Ltd

Study record dates

Study Major Dates

• Study Start (Actual): September 21, 2020
• Primary Completion (Actual): January 11, 2021
• Study Completion (Actual): January 11, 2021

Study Registration Dates

• First Submitted: July 3, 2020
• First Submitted That Met QC Criteria: July 9, 2020
• First Posted (Actual): July 15, 2020

Study Record Updates

• Last Update Posted (Actual): July 14, 2021
• Last Update Submitted That Met QC Criteria: July 13, 2021
• Last Verified: July 1, 2021

More Information

Terms related to this study

• Keywords: Qishenyiqi Dripping Pills
• Other Study ID Numbers: TSL-TCM-QSYQDW-I

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No